Zacks Research Has Positive Forecast for PBYI Q1 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities researchers at Zacks Research boosted their Q1 2026 earnings per share estimates for shares of Puma Biotechnology in a research note issued to investors on Wednesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.07 per share for the quarter, up from their previous estimate of $0.06. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s FY2026 earnings at $0.28 EPS and Q1 2027 earnings at $0.13 EPS.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.29. The company had revenue of $59.10 million during the quarter, compared to analysts’ expectations of $52.50 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%.

A number of other brokerages have also recently issued reports on PBYI. StockNews.com raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th.

Puma Biotechnology Stock Performance

Shares of Puma Biotechnology stock opened at $3.08 on Thursday. Puma Biotechnology has a 12 month low of $2.23 and a 12 month high of $5.26. The firm has a market capitalization of $152.80 million, a P/E ratio of 6.42 and a beta of 1.34. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $3.12 and a two-hundred day simple moving average of $3.03.

Hedge Funds Weigh In On Puma Biotechnology

Large investors have recently modified their holdings of the stock. Gateway Wealth Partners LLC purchased a new position in Puma Biotechnology in the fourth quarter worth about $31,000. Tower Research Capital LLC TRC raised its holdings in Puma Biotechnology by 167.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 6,351 shares during the last quarter. Graham Capital Management L.P. bought a new position in Puma Biotechnology in the 4th quarter valued at approximately $33,000. ProShare Advisors LLC purchased a new stake in Puma Biotechnology during the 4th quarter valued at $36,000. Finally, C2C Wealth Management LLC purchased a new stake in Puma Biotechnology during the 4th quarter valued at $37,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.